ABSTRACT
4CPS-018 Table 1MARCH-JUNE 2020 MAY-AUGUST 2021 EVOLUTION 2020-2021 CICU CMW GLOBAL CICU CMW GLOBAL CICU CMW GLOBAL BED-DAYS 573 2346 2919 493 2114 2607 Co-amoxiclav DDD/100BED-DAYS 0,9 22 17,9 1,2 21,1 17,3 +0,3 (33,3%) -0,9 (-4%) -0,6 (-3,4%) 3rd generation cephalosporins DDD/100BED-DAYS 32,3 8,9 13,5 35,7 3,5 9,6 +3,4 (10,5%) -5,4 (-60%) -3,9 (-28,9%) Antipseudomonal antibiotics DDD/100BED-DAYS 16,1 9,1 10,5 27,8 5,9 10 +11,7 (72,7%) -3.2 (-35.1%) -0,5 (-4,%) Quinolones DDD/100BED-DAYS 2,3 3,6 3,4 10,8 1,4 3,2 +8,5 (370%) -2,2 (-61,1%) -0,2 (-5,9%) Anti-MRSA antibiotics DDD/100BED-DAYS 23,4 3,4 7,3 18,6 2 5,1 -4,8 (-20,5%) -1,4 (-41,2%) -2,2 (-30,1%) Antifungal treatments DDD/100BED-DAYS 4,4 1 1,6 22,9 0 4,4 +18,5 (420%) -4,4 (-100%) +2,8 (175%) Total antimicrobial consumption DDD/100BED-DAYS 135,1 62,6 76,8 187,3 43,7 70,8 +52,2 (38,6%) -18,9 (-30,2%) -6 (-7,8%) The antibiotic use in the two periods showed a significance correlation (p<0,001).Conclusion and RelevanceThere is a light decrease of antimicrobial prescriptions in all COVID-19 patients.There is an important decrease in antimicrobial use in CMW and a considerable increase in CICU.These results suggest the need for more antimicrobial stewardship programmes in CICUReferences and/or AcknowledgementsConflict of InterestNo conflict of interest
ABSTRACT
The availability of accurate and rapid diagnostic tools for COVID-19 is essential for tackling the ongoing pandemic. In this context, researchers in the UK have started testing a new Lateral Flow Device (LFD) based on proprietary Biotinylated anti SARS-CoV-2 S1 Affimer(R) technology that binds to the SARS-CoV2-S1 protein in anterior nasal swab samples, generating an ultra-sensitive method for detection. This international study aimed to compare its performance against other available antigen-detecting rapid diagnostic tests (Ag-RDTs) in a real-world clinical setting. The study was completed under the frame of Project SENSORNAS RTC-20176501 in collaboration with MiRNAX Biosens Ltd. and Hospital Carlos III, it was documented internally and deposited in agreement to the ISO 13485 norm. All the data obtained are currently under submission and review from the Ethics Committee of Universidad Autonoma de Madrid.
Subject(s)
COVID-19 , Gerstmann Syndrome , Neuromyelitis OpticaABSTRACT
Background and aimsQuick, user-friendly and sensitive diagnostic tools are the key to controlling the spread of the SARS-CoV-2 pandemic in the new epidemiologic landscape. The aim of this work is to characterise a new Covid-19 antigen test that uses an innovative chromatographic Affimer(R)-based technology designed for the qualitative detection of SARS-CoV-2 antigen. As rapid technology to detect Covid-19, the test was extensively characterised in vitro. Once the analytical parameters of performance were set, the test system was challenged in a test field study. The aim of this study was to evaluate its diagnostic accuracy, as compared by the gold standard RT-PCR and other existing lateral flow tests.